Miles Congreve

Overview

Best Publications

• A 'rule of three' for fragment-based lead discovery?

  Miles Congreve;Robin Carr;Chris Murray;Harren Jhoti

  1637
  Citations

• Fragment-based lead discovery

  David C. Rees;Miles Congreve;Christopher W. Murray;Robin Carr

  1012
  Citations

• Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B

  Rob L. M. van Montfort;Miles Congreve;Dominic Tisi;Robin Carr

  769
  Citations

• Recent Developments in Fragment-Based Drug Discovery

  Miles Congreve;Gianni Chessari;Dominic Tisi;Andrew J. Woodhead

  739
  Citations

• Keynote review: Structural biology and drug discovery

  Miles Congreve;Christopher W. Murray;Tom L. Blundell

  474
  Citations

• Fragment-based lead discovery: leads by design

  Robin A.E. Carr;Miles Congreve;Christopher W. Murray;David C. Rees

  472
  Citations

• Impact of GPCR Structures on Drug Discovery

  Miles Congreve;Chris de Graaf;Nigel A. Swain;Christopher G. Tate

  395
  Citations

• Discovery of 1,2,4-Triazine Derivatives as Adenosine A(2A) Antagonists using Structure Based Drug Design

  Miles Congreve;Stephen P Andrews;Andrew S Dore;Kaspar Hollenstein

  361
  Citations

• Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.

  Andrew J. Woodhead;Hayley Angove;Maria G. Carr;Gianni Chessari

  347
  Citations

• Intracellular allosteric antagonism of the CCR9 receptor

  Christine Oswald;Mathieu Rappas;James Kean;Andrew S. Doré

  278
  Citations

• Progress in structure based drug design for G protein-coupled receptors.

  Miles Congreve;Christopher J. Langmead;Jonathan S. Mason;Fiona H. Marshall

  257
  Citations

• Identification of Novel P38Alpha Map Kinase Inhibitors Using Fragment-Based Lead Generation.

  Adrian L Gill;Martyn Frederickson;Anne Cleasby;Steven J Woodhead

  237
  Citations

• Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency.

  Christopher W. Murray;Maria G. Carr;Owen Callaghan;Gianni Chessari

  230
  Citations

• Crystal structure of the GLP-1 receptor bound to a peptide agonist

  Ali Jazayeri;Mathieu Rappas;Alastair J. H. Brown;James Kean

  217
  Citations

• Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency

  Unknown

  213
  Citations

• Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).

  John A. Christopher;Sarah J. Aves;Kirstie A. Bennett;Andrew S. Doré

  209
  Citations

• New insights from structural biology into the druggability of G protein-coupled receptors

  Jonathan S. Mason;Andrea Bortolato;Miles Congreve;Fiona H. Marshall

  193
  Citations

• Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design.

  John A. Christopher;Jason Brown;Andrew S. Doré;James C. Errey

  184
  Citations

• Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors

  Nigel Howard;Chris Abell;Wendy Blakemore;Gianni Chessari

  184
  Citations

• The impact of GPCR structures on pharmacology and structure-based drug design.

  Miles Congreve;Fiona Marshall

  182
  Citations

• Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase.

  Miles Congreve;David Aharony;Jeffrey Albert;Owen Callaghan

  175
  Citations